Galectin-3 blockade reduces renal fibrosis in two normotensive experimental models of renal damage

PLoS ONE

Volumn 11, Issue 11, 2016, Pages

  Martinez Martinez, Ernesto ^a   Ibarrola, Jaime ^a   Calvier, Laurent ^b   Fernandez Celis, Amaya ^a   Leroy, Celine ^b   Cachofeiro, Victoria ^c   Rossignol, Patrick ^b   Lopez Andres, Natalia ^a,b  

^a Red de Investigación en Servicios de Salud en Enfermedades Crónicas   (Spain)

^b UNIVERSITÉ DE LORRAINE   (France)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA SMOOTH MUSCLE ACTIN; BETA CATENIN; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; FIBRONECTIN; GALECTIN 3; KIDNEY INJURY MOLECULE 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OSTEOPONTIN; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN; PECTIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA STENOSIS; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DISEASE SEVERITY; EPITHELIAL MESENCHYMAL TRANSITION; HISTOPATHOLOGY; INTERSTITIAL NEPHRITIS; KIDNEY FIBROSIS; KIDNEY INJURY; MALE; NONHUMAN; OBESITY; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS INHIBITION; PROTEIN URINE LEVEL; RAT; UPREGULATION; ACUTE KIDNEY INJURY; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; AORTIC VALVE STENOSIS; COMPLICATION; DISEASE MODEL; FIBROSIS; KIDNEY; LIPID DIET; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; WISTAR RAT;

ACUTE KIDNEY INJURY; ANIMALS; AORTIC VALVE STENOSIS; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FIBROSIS; GALECTIN 3; KIDNEY; MALE; OBESITY; PECTINS; RATS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84994633266     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0166272     Document Type: Article

References (32)

1. Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007; 72(3):247-59. doi: 10.1038/sj.ki.5002343 PMID: 17568785
2. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003; 139(4):244-52. PMID: 12965979
3. Becker GJ, Hewitson TD. The role of tubulointerstitial injury in chronic renal failure. Curr Opin Nephrol Hypertens. 2000; 9(2):133-8. PMID: 10757217
4. Anderson S, Halter JB, Hazzard WR, Himmelfarb J, Horne FM, Kaysen GA, et al. Prediction, progression, and outcomes of chronic kidney disease in older adults. Clin J Am Soc Nephrol. 2009; 20(6):1199-209.
5. Fragiadaki M, Mason RM. Epithelial-mesenchymal transition in renal fibrosis - evidence for and against. Int J Clin Exp Pathol. 2011; 92(3):143-50.
6. Wicks SE, Nguyen TT, Breaux C, Kruger C, Stadler K. Diet-induced obesity and kidney disease - In search of a susceptible mouse model. Biochimie. 2016; 124:65-73. doi: 10.1016/j.biochi.2015.08.001 PMID: 26248309
7. Najjar M, Yerebakan H, Sorabella RA, Guglielmetti L, Vandenberge J, Kurlansky P, et al. Reversibility of chronic kidney disease and outcomes following aortic valve replacementdagger. Interact Cardiovasc Thorac Surg. 2015; 21(4):499-505. doi: 10.1093/icvts/ivv196 PMID: 26180091
8. Aregger F, Wenaweser P, Hellige GJ, Kadner A, Carrel T, Windecker S, et al. Risk of acute kidney injury in patients with severe aortic valve stenosis undergoing transcatheter valve replacement. Nephrol Dial Transplan. 2009; 24(7):2175-9.
9. Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol. 2008; 172(2):288-98. doi: 10.2353/ajpath.2008.070726 PMID: 18202187
10. Chen SC, Kuo PL. The Role of Galectin-3 in the Kidneys. Int J Mol Sci. 2016; 17(4).
11. Calvier L, Martinez-Martinez E, Miana M, Cachofeiro V, Rousseau E, Sadaba JR, et al. The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. JACC Heart failure. 2015; 3(1):59-67. doi: 10.1016/j.jchf.2014.08.002 PMID: 25458174
12. Kolatsi-Joannou M, Price KL, Winyard PJ, Long DA. Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury. PloS one. 2011; 6(4):e18683. doi: 10.1371/journal.pone.0018683 PMID: 21494626
13. Frenay AR, Yu L, van der Velde AR, Vreeswijk-Baudoin I, Lopez-Andres N, van Goor H, et al. Pharmacological inhibition of galectin-3 protects against hypertensive nephropathy. Am J Physiol Renal Physiol. 2015; 308(5):F500-9. doi: 10.1152/ajprenal.00461.2014 PMID: 25503732
14. Martinez-Martinez E, Lopez-Andres N, Jurado-Lopez R, Rousseau E, Bartolome MV, Fernandez-Celis A, et al. Galectin-3 Participates in Cardiovascular Remodeling Associated With Obesity. Hypertension. 2015; 66(5):961-9. doi: 10.1161/HYPERTENSIONAHA.115.06032 PMID: 26351031
15. Nishiyama J, Kobayashi S, Ishida A, Nakabayashi I, Tajima O, Miura S, et al. Up-regulation of galectin-3 in acute renal failure of the rat. Am J Pathol. 2000; 157(3):815-23. doi: 10.1016/S0002-9440(10)64595-6 PMID: 10980121
16. Tang WH, Shrestha K, Shao Z, Borowski AG, Troughton RW, Thomas JD, et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol. 2011; 108(3):385-90. doi: 10.1016/j.amjcard.2011.03.056 PMID: 21600537
17. O'Seaghdha CM, Hwang SJ, Ho JE, Vasan RS, Levy D, Fox CS. Elevated galectin-3 precedes the development of CKD. Clin J Am Soc Nephrol. 2013; 24(9):1470-7.
18. Okamura DM, Pasichnyk K, Lopez-Guisa JM, Collins S, Hsu DK, Liu FT, et al. Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis. Am J Physiol Renal Physiol. 2011; 300(1):F245-53. doi: 10.1152/ajprenal.00326.2010 PMID: 20962111
19. Pugliese G, Pricci F, Iacobini C, Leto G, Amadio L, Barsotti P, et al. Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice. FASEB J. Discipline · Biology. 2001; 15(13):2471-9.
20. Fernandes Bertocchi AP, Campanhole G, Wang PH, Goncalves GM, Damiao MJ, Cenedeze MA, et al. A Role for galectin-3 in renal tissue damage triggered by ischemia and reperfusion injury. Transpl Int. 2008; 21(10):999-1007. doi: 10.1111/j.1432-2277.2008.00705.x PMID: 18657091
21. Liu HY, Huang ZL, Yang GH, Lu WQ, Yu NR. Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model. World J. Gastroenterol. 2008; 14(48):7386-91. doi: 10.3748/wjg.14.7386 PMID: 19109874
22. Martinez-Martinez E, Calvier L, Fernandez-Celis A, Rousseau E, Jurado-Lopez R, Rossoni LV, et al. Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension. Hypertension. 2015; 66(4):767-75. doi: 10.1161/HYPERTENSIONAHA.115.05876 PMID: 26238446
23. Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. Clin J Am Soc Nephrol. 2010; 21(2):212-22.
24. Traber PG, Chou H, Zomer E, Hong F, Klyosov A, Fiel MI, et al. Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PloS one. 2013; 8(10):e75361. doi: 10.1371/journal.pone.0075361 PMID: 24130706
25. Mackinnon AC, Gibbons MA, Farnworth SL, Leffler H, Nilsson UJ, Delaine T, et al. Regulation of transforming growth factor-beta1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med. 2012; 185(5):537-46. doi: 10.1164/rccm.201106-0965OC PMID: 22095546
26. Martinez-Martinez E, Calvier L, Rossignol P, Rousseau E, Fernandez-Celis A, Jurado-Lopez R, et al. Galectin-3 inhibition prevents adipose tissue remodelling in obesity. Int J Obes. 2016; 40(6):1034-8.
27. McClellan WM, Flanders WD. Risk factors for progressive chronic kidney disease. Clin J Am Soc Nephrol. 2003; 14(7 Suppl 2):S65-70.
28. Strutz F, Zeisberg M. Renal fibroblasts and myofibroblasts in chronic kidney disease. Clin J Am Soc Nephrol. 2006; 17(11):2992-8.
29. Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. Clin J Am Soc Nephrol. 2010; 21(11):1819-34.
30. Lee HS, Kim C, Kim SB, Kim MG, Park D. Epithin, a target of transforming growth factor-beta signaling, mediates epithelial-mesenchymal transition. Biochem Biophys Res Commun. 2010; 395(4):553-9. doi: 10.1016/j.bbrc.2010.04.065 PMID: 20398629
31. Mori T, Kawara S, Shinozaki M, Hayashi N, Kakinuma T, Igarashi A, et al. Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: A mouse fibrosis model. J Cell Physio. 1999; 181(1):153-9.
32. Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage?. Clin J Am Soc Nephrol. 2006; 17(11):2974-84.